Wire · regulatory
Treasury Draft Regulations Would Prohibit Certain U.S. Investments in Biotech Sector in China
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 3 November 2026 · Fusion42 review
The U.S. Treasury has proposed regulations under the COINS Act that would prohibit certain U.S. investments in Chinese biotechnology companies, potentially restricting cross-border investments and joint ventures by March 2027. The proposal excludes licensing transactions and targets entities involved in advanced biotech sectors related to pharmaceuticals, biomanufacturing, brain-computer interfaces, and automated scientific discovery.
This Wire brief sits within Fusion42's coverage of Biotech, and 5 sources have reported it between 23 Oct 2026 and 3 Nov 2026.
◆ ◆ The Wire takeaway
You face a shrinking window to close deals with Chinese biotech firms before new U.S. rules block most investments. Reassess all partnerships now and prepare for tougher restrictions on any joint ventures or acquisitions by March 2027.
◆ Coverage
5 sources · first reported 23 Oct 2026 · latest 3 Nov 2026
◆ Related on Wire
◆ Topics